GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apollo Endosurgery Inc (NAS:APEN) » Definitions » Long-Term Debt & Capital Lease Obligation

Apollo Endosurgery (Apollo Endosurgery) Long-Term Debt & Capital Lease Obligation : $36.81 Mil (As of Dec. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Apollo Endosurgery Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Apollo Endosurgery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $36.81 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Apollo Endosurgery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $36.81 Mil. Apollo Endosurgery's Total Assets for the quarter that ended in Dec. 2022 was $110.23 Mil. Apollo Endosurgery's LT-Debt-to-Total-Asset for the quarter that ended in Dec. 2022 was 0.33.

Apollo Endosurgery's LT-Debt-to-Total-Asset declined from Dec. 2021 (0.40) to Dec. 2022 (0.33). It may suggest that Apollo Endosurgery is progressively becoming less dependent on debt to grow their business.


Apollo Endosurgery Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Apollo Endosurgery's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollo Endosurgery Long-Term Debt & Capital Lease Obligation Chart

Apollo Endosurgery Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.19 18.55 56.58 52.99 36.81

Apollo Endosurgery Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.99 53.16 53.33 53.50 36.81

Apollo Endosurgery Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Apollo Endosurgery  (NAS:APEN) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Apollo Endosurgery's LT-Debt-to-Total-Asset ratio for the quarter that ended in Dec. 2022 is calculated as:

LT-Debt-to-Total-Asset (Q: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )/Total Assets (Q: Dec. 2022 )
=36.809/110.231
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Apollo Endosurgery Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Apollo Endosurgery's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollo Endosurgery (Apollo Endosurgery) Business Description

Traded in Other Exchanges
N/A
Address
1120 S. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, USA, 78746
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.
Executives
Antal Rohit Desai 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Sharon O'keefe director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffrey G. Black officer: Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Mike Gutteridge officer: VP, Int'l Sales and Marketing 1120 S. CAPITAL OF TEXAS HIGHWAY, BUILDING 1, SUITE #300, AUSTIN TX 78746
Cpmg Inc 10 percent owner 4215 WEST LOVERS LANE, SUITE 100, DALLAS TX 75209
Mcgaughy R Kent Jr director, 10 percent owner 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Chas Mckhann director, officer: President and CEO 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Pacitti director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
John R Barr director VI TECHNOLOGIES INC, 134 COOLIDGE AVENUE, WATERTOWN MA 02472
Neil Gagnon 10 percent owner 1370 AVENUE OF THE AMERICAS, 24TH FLOOR, NEW YORK NY 10019
Traweek James W Jr 10 percent owner 2000 MCKINNEY AVE, SUITE 2125, DALLAS TX 75201
Todd Newton director, officer: Chief Executive Officer 1120 S CAPITAL OF TX HWY, BUILDING ONE, STE 300, AUSTIN TX 78746
Stonepine Capital, L.p. 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Matthew S Crawford director, 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746

Apollo Endosurgery (Apollo Endosurgery) Headlines

From GuruFocus